Skip to main content
. 2016 Oct 11;6:34631. doi: 10.1038/srep34631

Figure 5.

Figure 5

(a) Analysis of VEGF concentrations in patients receiving bevacizumab. (b) Analysis of VEGF concentrations in patients receiving ranibizumab.